Skip to the story

Vol. I · No. 1

Morning ColumnThe letter

Current News · Sourced report

MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

News Desk · Nov 9, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 9, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication. Nov 9, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.